In clinical studies, REYATAZ (with or without ritonavir) has been shown to induce dyslipidaemia to a lesser extent than comparators.
En estudios clínicos, REYATAZ (con o sin ritonavir) ha demostrado que induce dislipemia en menor proporción que los comparadores.